NCT02466750

Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine

Phase 2 Open-Label Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92, in Healthy Adult Subjects at Risk of Exposure to Western Equine Encephalitis Virus

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: U.S. Army Medical Research and Development Command · Federal
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study is being conducted to collect safety and immunogenicity data for the WEE vaccine, TSI-GSD 210. Enrollment in this protocol is offered for personnel who enter areas where this virus is used in research or is endemic (an area where this disease process is found to occur frequently).

Conditions

• Western Equine Encephalitis

Interventions

Type	Name	Description
BIOLOGICAL	Western Equine Encephalitis (WEE) Vaccine	Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92

Timeline

• Start date: 2015-12-15
• Primary completion: 2021-06-01
• Completion: 2021-12-01
• First posted: 2015-06-09
• Last updated: 2021-02-11

Locations

1 site across 1 country: United States